<DOC>
	<DOC>NCT00928330</DOC>
	<brief_summary>This multicenter, Phase Ib study is an open label, dose escalation, three-arm study evaluating the safety, tolerability, pharmacokinetics, and activity of oral (PO) GDC 0941 administered in combination with either intravenous (IV) infusion of T-DM1 or IV infusion of trastuzumab.</brief_summary>
	<brief_title>Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Ado-trastuzumab emtansine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Maytansine</mesh_term>
	<criteria>Histologically documented locally advanced or metastatic breast cancer that has progressed on at least one trastuzumabbased regimen in the metastatic or locally advanced setting HER2positive disease documented by one of the following results using FDAapproved testing methods: FISHpositive, chromogenic in situ hybridization (CISH)positive, or IHC 3 + by local laboratory assessment Life expectancy &gt;= 90 days Agreement to use an effective form of contraception for the duration of the study History of Grade &gt;= 3 hypersensitivity reaction to trastuzumab, or Grade &gt;= 1 with the most recent trastuzumab infusion before study entry, or continued requirement for prolonged trastuzumab infusions to prevent hypersensitivity reactions History of intolerance to trastuzumab and/or adverse events related to trastuzumab that resulted in trastuzumab being permanently discontinued Prior anticancer therapy (e.g., biologic or other targeted therapy, chemotherapy, hormonal therapy) within 2 weeks prior to Day 1 Prior investigational anticancer therapy within 4 weeks prior to Day 1 Grade &gt;= 2 peripheral neuropathy History of Grade &gt;= 3 hyperglycemia (fasting) History of Type 1 or Type 2 diabetes requiring daily medication History of clinically significant cardiac or pulmonary dysfunction History of malabsorption syndrome or other condition that would interfere with enteral absorption Clinically significant history of liver disease, including cirrhosis, current alcohol abuse, or current known active infection with HIV, hepatitis B virus, or hepatitis C virus Any condition requiring anticoagulants, such as warfarin, heparin, or thrombolytic agents Any condition requiring &gt; 2 grams of acetaminophen daily Need for current chronic corticosteroid therapy Pregnancy, lactation, or breastfeeding Current severe, uncontrolled systemic disease (e.g., clinically significant cardiovascular, pulmonary, or metabolic disease) Major surgical procedure or significant traumatic injury within 28 days prior to Day 1, or anticipation of the need for major surgery during the course of study treatment Symptomatic hypercalcemia requiring continued use of bisphosphonate therapy Known brain metastases that are untreated, symptomatic, or require therapy to control symptoms</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>TDM-1</keyword>
	<keyword>HER2</keyword>
	<keyword>HER2+</keyword>
	<keyword>HER2+ Breast Cancer</keyword>
	<keyword>HER-2</keyword>
	<keyword>MBC</keyword>
	<keyword>Trastuzumab emtansine</keyword>
</DOC>